Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $25.11 USD
Change Today +0.06 / 0.24%
Volume 408.9K
QGEN On Other Exchanges
Symbol
Exchange
Xetra
NASDAQ GS
As of 8:10 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

Spoorstraat 50

Venlo, 5911 KJ

Netherlands

Phone: 31 77 320 8400

Fax: 31 77 320 8409

formation. Among the automation platforms that contribute to QIAGEN’s business: QIAsymphony is a modular system that has launched integrated workflow consolidation and laboratory automation, making workflows more efficient and helping to disseminate standardized, clinically proven molecular diagnostics. The company’s fully integrated QIAsymphony RGQ, launched in 2010, includes three modules - QIAsymphony SP for sample preparation, QIAsymphony AS for assay setup, and its real-time PCR platform Rotor-Gene Q. EZ1 Advanced XL performs automated nucleic acid purification for a range of sample types relevant for molecular diagnostics, human identity testing, forensics, biomedical research, and gene expression analysis. QIAcube is a sample processing instrument that incorporates novel and proprietary technologies allowing users to fully automate the use of all QIAGEN technologies originally designed for manual processing of samples. QIAcube HT enables automated mid- to high-throughput nucleic acid purification in 96-well format using silica membrane technology. Users can purify DNA, RNA, and miRNA from any type of sample, including cells, tissues, and food material, as well as from bacteria and viruses in animal samples. Rotor-Gene Q, the rotary real-time PCR cycler system, uses real-time PCR reactions to make sequences of DNA and RNA visible through amplification and quantifiable. It is an integral component of the QIAsymphony RGQ system. PyroMark is a high-resolution detection platform with Pyrosequencing technology that enables real-time analysis and quantification of genetic mutations and DNA methylation patterns. QIAgility is a compact benchtop instrument that enables rapid, high-precision PCR setup. QIAxcel replaces traditional slab-gel analysis, eliminating time-consuming nucleic acid separation methods in low- to high-throughput laboratories. ESEQuant Tube Scanners enable Point of Need testing in healthcare and other applications. These portable, battery-operated optical measurement devices permit low-throughput molecular testing in physician practices, emergency rooms, remote areas, and other settings with limited or delayed access to laboratory infrastructure. Customers The company sells to four major customer classes: Molecular Diagnostics comprising healthcare providers engaged in patient care including Prevention, Profiling of diseases, Personalized Healthcare and Point of Need testing; Applied Testing comprising government or industry customers using molecular technologies in fields, such as forensics, veterinary diagnostics and food safety testing; Pharma comprising pharmaceutical and biotechnology companies using molecular testing to support drug discovery, translational medicine and clinical development efforts; Academia comprising researchers exploring the secrets of life, such as disease mechanisms and pathways, in some cases translating findings into drug targets or other products; Intellectual Property As of December 31, 2014, the company owned 273 issued patents in the United States, 175 issued patents in Germany and 1,037 issued patents in other major industrialized countries. The company had 935 pending patent applications. Regulations Other Fraud and Abuse Laws The company must comply with a variety of other laws, such as laws prohibiting false claims for reimbursement under Medicare and Medicaid, all of which can also be triggered by violations of federal anti-kickback laws; the Health Insurance Portability and Accounting Act of 1996, which makes it a federal crime to commit healthcare fraud and make false statements; and the Federal Trade Commission Act and similar laws regulating advertisement and consumer protections. Competition The company’s competitors include Promega Corp.; EMD Millipore or Merck Millipore; Macherey-Nagel GmbH; Thermo Fisher; Promega Corp.; Sigma-Aldrich Corp.; Roche Diagnostics; Abbott; Siemens; Cepheid; and Hologic. History QIAGEN N.V. was founded in 1986.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
QGEN:US $25.11 USD +0.06

QGEN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bio-Reference Laboratories Inc $33.35 USD -0.41
BioMerieux €103.75 EUR +4.08
Cepheid $56.71 USD -1.36
Myriad Genetics Inc $34.60 USD +0.13
PerkinElmer Inc $53.39 USD 0.00
View Industry Companies
 

Industry Analysis

QGEN

Industry Average

Valuation QGEN Industry Range
Price/Earnings 53.3x
Price/Sales 4.4x
Price/Book 2.4x
Price/Cash Flow 40.0x
TEV/Sales 3.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QIAGEN N.V., please visit www.qiagen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.